Cheaper versions of medications to treat obesity, like Ozempic and Wegovy, could be on the market in Canada as soon as ...

This generic GLP-1 is liraglutide for injection (the generic version of Victoza). It differs from Wegovy because its active ingredient is liraglutide, not semaglutide.

Own-label versions of the weight-loss injection semaglutide may go on sale in six years’ time and could cost as little as £10 a month.

The most popular GLP-1 weight-loss drugs may not face competition from cheaper generic versions until the early 2030s.

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced ...

The US Food and Drug Administration on Monday approved Hikma Pharmaceuticals’ generic version of Novo Nordisk’s diabetes drug, Victoza, clearing the way for the launch of another copy of the ...

Novo has, notably, kept up with its patent fees in the US, and generic semaglutide won't hit American shelves until at least 2032 — but as Saynor alluded to, they might be able to drive up to ...

Compounding pharmacies producing cheaper semaglutide products have been given notice they will soon have to stop, as the drug is no longer on the FDA shortage list.

Brazilian drugmaker Hypera plans to launch next year a generic version of semaglutide, the active ingredient of Novo Nordisk's blockbuster diabetes and weight-loss drug Ozempic, Hypera's chief ...

Compounded semaglutide is a non-FDA-approved alternative to products that contain semaglutide, such as Ozempic. Learn how the safety and efficacy of compounded semaglutide compares with Ozempic.

U.S. representative from Austin asks Health and Human Services secretary to push for generic licensing of semaglutide weight-loss medications to lower costs.

The first-ever generic GLP-1 medication — a duplicate version of Teva Pharmaceuticals' Victoza — was launched on June 25. Doctors explain the potential benefits for diabetes patients.